Two COVID-19 mRNA doses efficiently primed the spike-specific CD4+ T cells in all participants (17/17) and throughout the period post-primary vaccine series, CD4+ responses remained at clearly detectable levels, although the responses decreased slightly but non-significantly within eight months after the second dose (Figure 3B). The gene discussed is CD4; the disease is COVID-19.